Organicell Regenerative Medicine Inc (PK:BPSR)

Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers
See Regulatory Filings on SEC
Company Contact
Address: 4045 Sheridan Ave Ste 239
MIAMI FL 33140-3665
Tel: N/A
IR: See website
Key People
Albert Mitrani
President, Chief Executive Officer, Treasurer, Secretary, Director
Ian T. Bothwell
Chief Financial Officer, Director
Bruce Werber
Chief Operating Officer, Director
Terrell Suddarth
Chief Technology Officer, Director
Maria Ines Mitrani
Chief Scientific Officer, Director
Business Overview
Organicell Regenerative Medicine, Inc., formerly Biotech Products Services and Research, Inc., is engaged in the healthcare industry, principally focused on supplying products and services related to the field of regenerative anti-aging medicine (RAAM). The Company focuses on the referral of cellular therapies for treating neurodegenerative, inflammatory and autoimmune conditions for patients across the world. The Company intends to distribute the RAAM Products and market RAAM-related services through a referral network of doctors and clinics. It also intends to develop a network of branded destination domestic and international clinics capable of providing RAAM-based therapies and treatments. Its RAAM-related operations are conducted through its subsidiaries, Beyond Cells Corp., engaged in providing anti-aging and cellular therapy patient referral and product sales, and General Surgical of Florida, Inc., engaged in sale of cellular therapy products to doctors and hospitals.
Financial Overview
For the fiscal year ended 31 October 2018, Organicell Regenerative Medicine Inc revenues increased 69% to $965K. Net loss decreased 61% to $3.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and administrative expenses decrease of 53% to $4.2M (expense), Interest expense decrease of 60% to $228K (expense).
Employees: 5 as of Oct 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $34.56M as of Oct 31, 2018
Annual revenue (TTM): $0.96M as of Oct 31, 2018
EBITDA (TTM): -$3.48M as of Oct 31, 2018
Net annual income (TTM): -$3.46M as of Oct 31, 2018
Free cash flow (TTM): -$0.52M as of Oct 31, 2018
Net Debt Last Fiscal Year: $0.34M as of Oct 31, 2018
Shares outstanding: 712,973,613 as of May 22, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization